Covance price target raised to $115 from $105 at Jefferies Jefferies raised its price target for Covance shares to $115 citing the company's earnings power and expectations that consensus estimates can go higher. The firm keeps a Buy rating on the stock.
LabCorp downgraded to Hold from Buy at Deutsche Bank Deutsche Bank downgraded LabCorp (LH) to Hold saying revenue synergies from the Covance (CVD) acquisition are "hard to envision." The firm believes LabCorp is now less of a pure play in the Clinical Labs space and lowered its price target for shares to $115 from $120. Deutsche coupled the downgrade with an upgrade of peer Quest (DGX).